Genetic Tool Developed for Diagnosing Pulmonary Fibrosis

Researchers have developed and validated a genetic scoring tool that could enhance the diagnosis of idiopathic pulmonary fibrosis (IPF) and predict which patients face the highest risk of severe outcomes, such as mortality or lung transplantation. The tool, evaluated in a multinational study involving over 570,000 individuals, was co-led by teams from Mayo Clinic and Brigham and Women’s Hospital. By analyzing genetic variants linked to IPF, the score provides a quantitative measure to aid clinicians in distinguishing IPF from other lung conditions and assessing disease severity, addressing challenges posed by the condition’s variable presentation and progression.

The study, published in a peer-reviewed journal, integrated data from diverse populations across multiple continents, enhancing the tool’s generalizability. Researchers identified 17 genetic loci strongly associated with IPF, which were combined into a risk score. Patients with higher scores exhibited a significantly elevated likelihood of rapid disease progression and poorer survival rates. The findings underscore the role of genetic predisposition in IPF pathogenesis and offer a potential framework for personalized risk stratification. Clinicians could use the score alongside existing diagnostic criteria to tailor monitoring and treatment plans, potentially improving outcomes for a disease with limited therapeutic options.

This advancement marks a step forward in precision medicine for IPF, a chronic, progressive lung disease with an average survival rate of three to five years. While further validation in clinical settings is needed, the tool’s scalability and integration into routine care could streamline early detection and resource allocation for high-risk patients. The collaboration between leading medical institutions highlights the growing emphasis on genetic research to address unmet needs in complex respiratory disorders.